News

Neurology News Network for the week ending November 7, 2020.

Biogen’s investigational Alzheimer disease treatment is currently under review with a Prescription Drug User Fee Act target action date of March 7, 2021, if not earlier.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, described the challenges he’s faced when having to discuss a change in treatment strategies with his patients.

The decision was based on findings from the phase 3 THALES trial, which showed aspirin plus ticagrelor significantly reduced stroke and death compared with aspirin alone in patients with acute ischemic stroke or TIA.

Based on data from a study of 686 patients with subjective cognitive impairment or dementia, the PrecivityAD blood test correctly identified brain amyloid plaque status in 86% of the patients.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Indu Subramanian, MD.

The section chief of pediatric neurology at Nationwide Children’s Hospital spoke about the effect telemedicine has had on patients with Lennox-Gastaut syndrome throughout the COVID-19 pandemic.

CND Life Science’s Syn-One test marks the next step in synucleinopathy detection by offering a quick and minimally invasive procedure.

The new codes have broader implications in helping clinicians understand the morbidity and mortality related to the disorder.

The company’s implantable neurostimulation system uses its bioelectronic foil technology and aims to meet the needs of those with chronic migraine for whom therapy has failed.

This three-part, educational webinar series provides evidence-based information about the effects of cannabis on MS symptoms, including pain and spasticity.

The associate professor of neurology at Washington University in St. Louis discussed a number of recent advances in therapeutics, as well as diagnostic and measurement devices, in sleep medicine.

The researchers aim to fill the void of approved treatments for mild cognitive impairment, showing the potential of brain energy rescue strategies in this patient population.

The chief scientific officer at the Parkinson’s Foundation discussed PD GENEration, an initiative to provide genetic testing for patients with Parkinson disease.

Bruce Cree, MD, PhD, MAS, offers his perspective on recent trial results that put to bed a long line of inconsistent data on the utility of high-dose biotin for multiple sclerosis.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

A recently published critique of aducanumab's trial results calls for a third and definitive phase 3 study of the investigational agent, which is awaiting a decision from the FDA.

A 2-part webcast series geared toward MS nursing professionals and patients.

A 2-part webcast series geared toward MS nursing professionals and patients.

Findings from PD GENEration will contribute to the biological understanding of the disease and help researchers assess the impact of each mutation.

The director of the Montefiore Einstein Center for the Aging Brain discussed the details of his study that will evaluate motoric cognitive risk syndrome.

Contrary to prior findings, no evidence was found to support a protective association between leisure activity and risk of dementia.

The 12-month results from the phase 2 TOPAZ clinical trial are anticipated by the second quarter of 2021, according to Scholar Rock.

The percent change from baseline was lower in those who initiated ocrelizumab early than those initially on placebo for both T2 lesion volume and T1 hypointense lesion volume.

The associate professor of neurology at Washington University in St. Louis spoke to the need to improve the awareness for insomnia, which remains one of the most common sleep disorders.

In addition to recommendations for Alzheimer disease screening, the guidelines also covered stroke risk-related assessments which should be conducted for those with Down syndrome.

The findings suggest that poor speech-in-noise hearing may be an early marker of underlying dementia processes.

Here's what is coming soon to NeurologyLive.

The section chief of pediatric neurology at Nationwide Children’s Hospital provided his thoughts on raising awareness for Lennox-Gastaut syndrome on International LGS Day.